A potential protocol for treating pregnant individuals has been hypothesized based on previous studies and experience. The protocol consists of multiple levels and is described as follows. All patients were treated by strictly adhering to the pregnancy protocol.
1) Protocol for management of pregnant patients requiring minor oral surgical procedures
(1) Preoperative assessment
① In general, it is advisable to avoid surgical procedures during the first trimester if possible. The same treatment should be avoided in the late third trimester and deferred until after delivery. Only urgent surgical procedures that are drug-resistant and whose benefits outweigh the risk to the fetus should be performed.
② Categorization of the patients into first, second, and third trimesters demands specific considerations.
③ Obtaining an obstetrician's advice on fitness. Typically, tests include clinical examination; fetal ultrasound sonography or anomaly scans; assessments of risks to the growing fetus and placenta; certain investigations like complete blood count, HIV, and hepatitis B surface antigens tests; and medications are provided to reduce uterine contractility (tocolytics). A clinical examination and blood tests to detect gestational diabetes mellitus (which often develops after 20 weeks of pregnancy) and pre-eclampsia are typically performed. These include periodically measuring blood pressure and assessing the protein urea content of urine. A glucose tolerance test is used to identify gestational diabetes. These conditions must be handled by the proper specialty consultant.
④ Obtaining the patient’s informed, verbal, and written consent after thoroughly explaining the surgical treatment to be performed, its results, and any potential risks to the mother and fetus.
(2) Intraoperative safety measures
① To reduce nausea and possible aspiration during the procedure (especially in the first trimester), appointments should be arranged during the afternoon or evening. Pregnancy-related gastrointestinal problems frequently occur in the morning and cause nausea and vomiting. One hour prior to surgery, the administration of antiemetics such ondansetron should be considered. In addition, a high-power suction device must be ready in case vomiting occurs during the procedure.
② To prevent pressure from an enlarged uterus on the inferior vena cava, it is advisable to assume a left lateral posture with the right hip elevated 10°-15°. This can be performed by tucking a pillow beneath the right hip.
③ Careful monitoring of vital signs like oxygen saturation, pulse rate, respiratory rate, and blood pressure while performing the procedure. Observing for any possible fainting or loss of consciousness must also be carried out.
④ Pain management: Careful pain management is desired since discomfort during the procedure may cause uterine contractions or labor pain. To obtain the necessary anesthesia, lignocaine with adrenaline (1:180,000 or 1: 200,000) is a safe medication.
⑤ The length of the procedure must not exceed 30 minutes due to the patient’s somewhat unusual and challenging operating position.
(3) Postoperative safety measures
① Monitoring of the patient’s vitals during recovery.
② During recovery, the patient must be left in the left lateral position to prevent aspiration and syncope due to compression of the inferior vena cava. If necessary, 100% oxygen can be administered.
③ Provide the patient and her accompanying caretaker the appropriate postoperative instructions.
④ Consider category A and B medications for pain management and infection control that have been approved by the U.S. Food and Drug Administration. We used standard medications to achieve this goal.(
Table 1)
Table 1
List of standard drugs used during minor oral surgical procedures of pregnant patients in the current study
Drugs |
FDA category |
Safety during pregnancy |
Safety in lactation |
Potential teratogenic effects |
Antibiotics |
|
|
|
|
Amoxicillin, amoxicillin with clavulanic acid - injectable and oral |
B |
No proven risk in humans |
Not recommended |
|
Ceftriaxone - injectable |
B |
No proven risk |
Drug excreted in the milk in small quantities - acceptable with caution |
|
Cefixime |
B |
No proven risk |
Safety not proven |
Not determined |
Cefuroxime |
B |
No proven risk even in the first trimester |
Not recommended |
|
Metronidazole - oral - injectable |
B |
No proven risk |
Drug secreted in the milk at similar concentrations as that of plasma - discontinue breastfeeding temporarily |
Metronidazole had carcinogenic effects after prolonged and high-dose consumption |
Ciprofloxacin |
C |
Can be used even in the first trimester |
Secreted in the milk but considered to be usually compatible with breastfeeding |
Unlikely |
Clindamycin |
B |
No proven birth defects in the second and third trimesters. Safety of the drug in the first trimester data not known |
Drug secreted in the milk at one-tenth of the concentration in plasma. Monitoring of the child required for diarrhea and candidiasis. If symptoms appear, stop breast feeding temporarily. |
Undetermined |
Analgesics/NSAID |
|
|
|
|
Paracetamol |
Category - not assigned |
Traditionally supposed to be safe in pregnancy |
Secreted in the milk at low concentrations. Compatible with breastfeeding. |
Unlikely |
Aceclofenac/aceclofenac+seratiopeptidase |
Not recommended |
|
Not recommended |
|
Tramadol |
C |
Allowed in low dosages for short durations |
Not recommended |
Better to avoid the last trimester, baby may show withdrawal symptoms of the drug |
Diclofenac |
C - prior to 30 weeks of gestation D - after 30 weeks of gestation |
May be used with great caution before 30 weeks of gestation. Contraindicated in the 3rd trimester |
Not recommended |
Premature closure of the ductus arteriosus, fetal renal impairment, delay in labor |
Local anesthetics |
|
|
|
|
Lignocain hydrochloride |
B |
Safest local anesthetic |
|
Found to be non-teratogenic |
Antacids/antiemetics |
|
|
|
|
Doxyllamine succinate |
A |
Safest antiemetic |
May decrease the amount of breast milk, as the drug is secreted in milk and may cause drowsiness in the baby - not recommended |
Non teratogenic |
Pantoprazole, pantoprazole+domperidone |
C |
Recommended |
Drug excreted in milk with very little concentration, does not affect the baby |
|
Ondansetron |
B |
Recommended |
Not proven to have effects on the baby |
|

⑤ The patient has been informed to notify her physician if she experiences abdominal pain or spotting (mild vaginal bleeding brought on by placental detachment). The patient is also urged to keep an eye out for changes in fetal mobility and should consult her obstetrician if there is any suspicion of fetal mobility being altered.
All patients were monitored postoperatively until they fully recovered from their surgery, and further monitoring was performed until the baby was born. This was conducted to observe fetal loss (spontaneous abortion), preterm birth, low birth weight, or any congenital defect in the newborn and its association to the surgery.
The analysis was performed using IBM SPSS Statistics software (ver. 22.0; IBM, Armonk, NY, USA). Difference between groups were considered significant at P<0.05.